• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞周期蛋白D1在恶性潜能不确定的高分化甲状腺肿瘤中的表达

Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.

作者信息

Lamba Saini Monika, Weynand Birgit, Rahier Jacques, Mourad Michel, Hamoir Marc, Marbaix Etienne

机构信息

Anatomie pathologique, Cliniques universitaires Saint- Luc, Université catholique de Louvain, Avenue Hippocrate, 10/T-1, Brussels, 1200, Belgium.

Anatomie pathologique, CHU Dinant-Godinne, Université catholique de Louvain, Avenue Docteur G. Thérasse, 1, Yvoir, 5530, Belgium.

出版信息

Diagn Pathol. 2015 Apr 18;10:32. doi: 10.1186/s13000-015-0262-8.

DOI:10.1186/s13000-015-0262-8
PMID:25907675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4407836/
Abstract

BACKGROUND

Encapsulated follicular tumours with equivocal papillary thyroid carcinoma (PTC) type nuclear features continue to remain a challenge despite the recent attempts to classify these borderline lesions. The term 'well differentiated tumour of uncertain malignant potential (WDT-UMP)' was introduced to classify these tumours. The present study aimed to evaluate the role of a cell cycle regulator like cyclin D1 in these tumours along with assessment of other well established PTC markers like galectin-3, HBME-1, CK19.

METHODS

Thirteen cases of metastatic PTC, papillary microcarcinoma and follicular variant of PTC (FVPTC) were identified from a histological review of 510 cases. In addition, 13 cases of a subset of follicular adenomatoid nodules with focal areas showing nuclear features characteristic of PTC, identified as WDT-UMP, were also analyzed. Immunohistochemical analysis of galectin-3, HBME-1, CK19 and the proliferation markers Ki67 and cyclin D1 was performed. Lesions were analyzed for cyclin D1 gene amplification by fluorescent in-situ hybridization.

RESULTS

All WDT-UMP lesions showed immunolabelling of cyclin D1, Ki67; 11/ 13 cases showed immunolabelling of CK19; 10/13 cases showed immunolabelling of HBME-1 and 4/13 cases showed immunolabelling of galectin-3. Surrounding benign adenomatoid areas showed no to faint focal staining in all thirteen cases of cyclin D1, HBME-1 and galectin-3. A low rate of cyclin D1 gene amplification was identified in a significant proportion of cells in the WDT-UMP lesions as compared to surrounding benign adenomatoid areas.

CONCLUSIONS

Increased expression of cyclin D1 and amplification of its gene along with immunolabelling of HBME-1 in WDT-UMP lesions showing cytological features of papillary thyroid carcinoma within follicular adenomatoid nodules suggest that these areas could correspond to a precursor lesion of follicular variant of PTC. Overexpression of cyclin D1, associated with the amplification of the gene suggests that these WDT-UMP lesions are an intermediate between the benign and malignant groups making this group of lesions a reliable precursor of FVPTC.

VIRTUAL SLIDES

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1851820807142117.

摘要

背景

尽管最近尝试对这些临界性病变进行分类,但具有不明确的乳头状甲状腺癌(PTC)核特征的包膜滤泡性肿瘤仍然是一个挑战。引入了“恶性潜能不确定的高分化肿瘤(WDT-UMP)”这一术语来对这些肿瘤进行分类。本研究旨在评估细胞周期调节因子如细胞周期蛋白D1在这些肿瘤中的作用,并评估其他已确立的PTC标志物如半乳糖凝集素-3、HBME-1、细胞角蛋白19(CK19)。

方法

通过对510例病例的组织学回顾,确定了1

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/af610608f391/13000_2015_262_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/948ec6a9cb13/13000_2015_262_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/2a9ea0620562/13000_2015_262_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/b9f03cc9f2cd/13000_2015_262_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/79a29a96db9f/13000_2015_262_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/af610608f391/13000_2015_262_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/948ec6a9cb13/13000_2015_262_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/2a9ea0620562/13000_2015_262_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/b9f03cc9f2cd/13000_2015_262_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/79a29a96db9f/13000_2015_262_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ac2/4407836/af610608f391/13000_2015_262_Fig5_HTML.jpg

相似文献

1
Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.细胞周期蛋白D1在恶性潜能不确定的高分化甲状腺肿瘤中的表达
Diagn Pathol. 2015 Apr 18;10:32. doi: 10.1186/s13000-015-0262-8.
2
Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal.具有可疑核改变的包裹性滤泡状甲状腺肿瘤,所谓的低分化肿瘤,恶性潜能不确定:形态学、免疫组织化学和分子评估。
Cancer Sci. 2011 Jan;102(1):288-94. doi: 10.1111/j.1349-7006.2010.01769.x. Epub 2010 Nov 10.
3
Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.滤泡性甲状腺病变的病理诊断挑战。
Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3365-3376. doi: 10.31557/APJCP.2021.22.10.3365.
4
An Appraisal of Proliferation and Apoptotic Markers in Papillary Thyroid Carcinoma: An Automated Analysis.甲状腺乳头状癌中增殖和凋亡标志物的评估:自动化分析
PLoS One. 2016 Feb 10;11(2):e0148656. doi: 10.1371/journal.pone.0148656. eCollection 2016.
5
Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.CD56和E-钙黏蛋白表达在甲状腺乳头状癌与疑似甲状腺滤泡样病变鉴别诊断中的作用:E-钙黏蛋白的预后重要性
Int J Clin Exp Pathol. 2015 Apr 1;8(4):3670-80. eCollection 2015.
6
Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.恶性潜能不确定的甲状腺肿瘤:29例的形态学和免疫组织化学分析
Pathol Res Pract. 2015 Apr;211(4):320-5. doi: 10.1016/j.prp.2014.12.005. Epub 2014 Dec 22.
7
Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.HBME-1、CD56、半乳糖凝集素-3和细胞角蛋白-19在甲状腺乳头状癌及恶性潜能不确定的甲状腺肿瘤中的诊断价值
Rom J Morphol Embryol. 2014;55(1):49-56.
8
Immunohistochemical and morphometrical evaluation of well-differentiated thyroid tumor of uncertain malignant potential.具有不确定恶性潜能的高分化甲状腺肿瘤的免疫组织化学和形态计量学评估
Indian J Pathol Microbiol. 2019 Jan-Mar;62(1):17-23. doi: 10.4103/IJPM.IJPM_199_18.
9
Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.半乳糖凝集素-3、人鼠杂交瘤单克隆抗体-1、细胞角蛋白19、高分子量细胞角蛋白、细胞周期蛋白D1和p27(kip1)在甲状腺结节鉴别诊断中的诊断价值
J Korean Med Sci. 2007 Aug;22(4):621-8. doi: 10.3346/jkms.2007.22.4.621.
10
Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.中国东北地区 CK19、TG、Ki67 和半乳糖凝集素-3 表达对甲状腺乳头状癌的诊断意义。
Diagn Pathol. 2011 Dec 21;6:126. doi: 10.1186/1746-1596-6-126.

引用本文的文献

1
Concurrent papillary thyroid carcinoma and incidental cervical lymph node indolent B cell non-Hodgkin lymphoma: clinicopathological features, outcomes, and potential relationships.甲状腺乳头状癌合并偶然发现的颈部淋巴结惰性B细胞非霍奇金淋巴瘤:临床病理特征、结局及潜在关系
World J Surg Oncol. 2025 Apr 21;23(1):145. doi: 10.1186/s12957-025-03803-4.
2
Clinical and Paraclinical Considerations Regarding ki67's Role in the Management of Differentiated Thyroid Carcinoma-A Literature Review.临床和辅助检查考虑因素:Ki67 在分化型甲状腺癌管理中的作用——文献综述。
Medicina (Kaunas). 2024 May 7;60(5):769. doi: 10.3390/medicina60050769.
3

本文引用的文献

1
Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma.评估口腔和口咽鳞状细胞癌中 p53、p21、p27、细胞周期蛋白 D1 和 Ki67 的免疫组织化学表达。
J Oral Pathol Med. 2012 Jan;41(1):40-6. doi: 10.1111/j.1600-0714.2011.01071.x. Epub 2011 Aug 29.
2
Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.比较甲状腺转录因子-1、Ki-67、p63、p53、高分子量细胞角蛋白在甲状腺乳头状癌、滤泡癌和滤泡性腺瘤中的表达。
Ann Diagn Pathol. 2011 Apr;15(2):108-16. doi: 10.1016/j.anndiagpath.2010.11.005.
3
Clinical value of Cyclin D1 and P21 in the differential diagnosis of papillary thyroid carcinoma.
Cyclin D1 和 P21 在鉴别诊断甲状腺乳头状癌中的临床价值。
Diagn Pathol. 2023 Nov 11;18(1):123. doi: 10.1186/s13000-023-01410-z.
4
Multifocal Fibrosing Thyroiditis: an Under-recognized Mimicker of Papillary Thyroid Carcinoma.多灶性纤维性甲状腺炎:一种易被误诊为甲状腺乳头状癌的疾病。
Endocr Pathol. 2022 Sep;33(3):335-345. doi: 10.1007/s12022-022-09726-0. Epub 2022 Jul 11.
5
Co-Occurrence of Differentiated Thyroid Cancer and Second Primary Malignancy: Correlation with Expression Profiles of Mismatch Repair Protein and Cell Cycle Regulators.分化型甲状腺癌与第二原发性恶性肿瘤的同时发生:与错配修复蛋白和细胞周期调节因子表达谱的相关性
Cancers (Basel). 2021 Oct 31;13(21):5486. doi: 10.3390/cancers13215486.
6
Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.我们能否预测分化型甲状腺癌的行为?遗传和分子标志物的作用。
Medicina (Kaunas). 2021 Oct 19;57(10):1131. doi: 10.3390/medicina57101131.
7
Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer.下调 miR-193a-3p 通过靶向 cyclin D1 在甲状腺癌中的作用。
Mol Med Rep. 2020 Sep;22(3):2199-2218. doi: 10.3892/mmr.2020.11310. Epub 2020 Jul 8.
8
Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules.应用细胞周期蛋白 D1 免疫染色和基因组分析的细胞学筛查系统对甲状腺结节诊断的临床影响。
BMC Cancer. 2019 Mar 18;19(1):245. doi: 10.1186/s12885-019-5452-4.
9
Identification of potential functional genes in papillary thyroid cancer by co-expression network analysis.通过共表达网络分析鉴定甲状腺乳头状癌中的潜在功能基因
Oncol Lett. 2018 Oct;16(4):4871-4878. doi: 10.3892/ol.2018.9306. Epub 2018 Aug 14.
10
Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions.通过数字图像分析检测程序性死亡配体1的表达可提高包膜内滤泡性病变中甲状腺癌的诊断水平。
Oncotarget. 2018 Apr 13;9(28):19767-19782. doi: 10.18632/oncotarget.24833.
Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal.具有可疑核改变的包裹性滤泡状甲状腺肿瘤,所谓的低分化肿瘤,恶性潜能不确定:形态学、免疫组织化学和分子评估。
Cancer Sci. 2011 Jan;102(1):288-94. doi: 10.1111/j.1349-7006.2010.01769.x. Epub 2010 Nov 10.
4
Role of Ki-67 as a proliferative marker in lesions of thyroid.Ki-67作为甲状腺病变增殖标志物的作用。
Indian J Cancer. 2010 Jul-Sep;47(3):304-7. doi: 10.4103/0019-509X.64727.
5
Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma.包膜良好分化的滤泡型甲状腺癌在甲状腺癌死亡率中没有起重要作用。
Am J Surg Pathol. 2010 Jun;34(6):868-72. doi: 10.1097/PAS.0b013e3181dbee07.
6
Identification of borderline thyroid tumors by gene expression array analysis.基因表达谱分析鉴定甲状腺临界肿瘤。
Cancer. 2009 Dec 1;115(23):5421-31. doi: 10.1002/cncr.24616.
7
Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining.免疫组化标志物在甲状腺乳头状癌诊断中的应用:HBME1联合CK19免疫染色的效用
Mod Pathol. 2006 Dec;19(12):1631-7. doi: 10.1038/modpathol.3800705. Epub 2006 Sep 22.
8
Increasing incidence of thyroid cancer in the United States, 1973-2002.1973年至2002年美国甲状腺癌发病率上升情况。
JAMA. 2006 May 10;295(18):2164-7. doi: 10.1001/jama.295.18.2164.
9
Thyroid intrafollicular neoplasia (TIN) as a precursor of papillary microcarcinoma.
Ann Ital Chir. 2005 May-Jun;76(3):219-24.
10
Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.HBME-1、细胞角蛋白19和半乳糖凝集素-3免疫染色在甲状腺恶性肿瘤诊断中的应用价值。
Histopathology. 2005 Oct;47(4):391-401. doi: 10.1111/j.1365-2559.2005.02221.x.